ENDEAVOR

Endeavor Clinical Program

Marco A Costa, MD, PhD, FSCAI, FACC
Assistant Professor of Medicine, Director of Research
& Cardiovascular Imaging Core Laboratory

Platelet Aggregation and Activation

ENDEAVOR



Platelet deposition and activation occur at the injury site, leading to the release of cell-signaling molecules.

Components of the Endeavor Stent

ENDEAVOR



ENDEAVOR Clinical Program

ENDEAVOR I	Phase I FIM 36 month results
ENDEAVOR II	Double-blind Randomized Trial 24 month results
ENDEAVOR II CA Registry	Continued Access Safety 24 month results
ENDEAVOR III	Confirmatory Trial vs. Cypher 12 month results
ENDEAVOR IV	Confirmatory Trial vs. Taxus 30 day results
ENDEAVOR Japan	Single Arm Trial *Enrollment completed*
E-Five Registry	Real-World Performance and Safety Evaluation – *Enrollment completed*
PROTECT	Endeavor vs. Cypher Safety Study *8,000 patient RCT*

Endeavor Clinical Program

Extensive Clinical Experience



Total: N > 14,000

Endeavor Clinical Program

Extensive Clinical Experience



ENDEAVOR I

Phase I Trial "First In Man"

Single *De Novo* Native
Coronary Artery Lesions (Type A-C)
Stent Diameter: 3.0-3.5 mm
Stent Length: 18 mm
Lesion Length: <15 mm
Pre-dilatation required

N = 100 patients
8 sites
Australia and New Zealand

Primary Endpoints: MACE at 30 days and late loss (QCA) at 4 months
Secondary Endpoints: TVF and TLR at 9 months, late loss at 12 months
Antiplatelet therapy for 3 months 10 μg Zotarolimus per mm stent length

ENDEAVOR I

Patient Flowchart



ENDEAVOR I

Clinical Events to 3 Years

	0 - 12 Months n = 98	12 - 24 Months n = 98	24 - 36 Months n = 97	0 - 36 Months N = 97
MACE	2%	1%	3%	6%
Death	0	1%*	2%*	3%*
MI (all)	1%	0	0	1%
Q-wave	0	0	0	0
Non Q-wave	1%	0	0	1%
TLR	2%	0	1%	3%
TVR (non-TL)	0	2%	0	2%
TVF	2%	2%	1%	5%

*1x Metastatic melanoma 1x Metastatic adenocarcinoma, 1x Small cell bladder carcinoma.

ENDEAVOR II

Randomized, Double-Blind Trial Design

Single *De Novo* Native Coronary Artery Lesions
Stent Diameters: 2.25-3.5 mm
Stent Lengths: 18-30 mm (8/9 mm bailout)
Lesion Length: 14-27 mm
Pre-dilatation required

N = 1,200 patients
72 sites
Europe, Asia Pacific, Israel, New Zealand and Australia

Endeavor Stent
Active Arm
n = 600

Driver Stent
Control Arm
n = 600



Angio N = first 600
IVUS N = first 300
IVUS for overlapping stents

Primary Endpoint: TVF (cardiac death, MI, TVR) at 9 months
Dual antiplatelet therapy for 3 months. 10 μg Zotarolimus per mm stent length

ENDEAVOR II

Patient Flowchart



ENDEAVOR II

Clinical Outcomes

Primary Endpoint at 9 Month Follow-up



*Target Vessel Failure is a composite of target vessel revascularization, Q- or non Q-wave MI, or cardiac death.

Fajadet et al. *Circulation*. 2006;114:98-806.

ENDEAVOR II

TLR at 9 Months



Fajadet et al. *Circulation*. 2006;114:98-806.

ENDEAVOR II

Clinical Events at 24 Months



Fajadet et al. *Circulation*. 2006;114:98-806.

ENDEAVOR II

Event Free Survival at 2 Years



Fajadet et al. *Circulation*. 2006;114:98-806.

ENDEAVOR III

Multicenter Randomized Trial

3:1 Randomization
Single Blind - Single Vessel - No Staging

Single *De Novo* Native Coronary Lesion
Vessel Diameter: 2.5-3.5 mm
Lesion Length: 14-27 mm
Stent Lengths: 18-30 mm (8/9) mm bailout
Pre-dilatation required

Endeavor Stent
n = 327

N = 436 patients
30 sites
United States

Control Cypher Stent
n = 109



Primary Endpoint: In-segment late lumen loss by QCA at 8 months
Secondary Endpoints: TLR, TVR, TVF at 9 months & ABR at 8 months
Antiplatelet therapy for ³3 months 10 μg Zotarolimus per mm stent length

ENDEAVOR III

Patient Flowchart



Kandzari et al. JACC Vol. 48, No. 12, 2006.

ENDEAVOR III

Angiographic and IVUS Results at 8 Months

		Endeavor n = 277	Cypher n = 94	*P*-value
Angiographic f/u % (N)		85.8 (323)	83.2 (113)	.54
Pre RVD (mm)		2.75	2.79	.49
MLD (mm)	In-Stent	2.06	2.52	<.001
	In-Segment	1.91	2.16	<.001
DS (%)	In-Stent	24.9	11.0	<.001
	In-Segment	30.4	23.9	<.001
BAR (%)	In-Stent	9.7	2.1	.01
	In-Segment	12.3	4.3	.03
Late Loss (mm)	In-Stent	0.62	0.15	<.001
	In-Segment	0.36	0.13	<.001
Volume Obstruction (%)		15.9 (n = 187)	2.7 (n = 61)	<.001
Late Incomplete Apposition (%)		0.5 (1/189)	5.9 (4/68)	.02

Kandzari et al. JACC Vol. 48, No. 12, 2006.

ENDEAVOR III

Clinical Results at 12 Months

	Endeavor n = 320	Cypher n = 111	*P*-value
MACE (%)	7.8 (25)	8.1 (9)	1.00
Death	0.6 (2)*	0.9 (1)	1.00
Q-Wave MI	0	0	–
Non Q-Wave MI	0.6 (2)	3.6 (4)	.04
Emergent CABG	0	0	–
TLR	6.6 (21)	3.6 (4)	.35
CABG	0.9 (3)	0	.57
PCI	5.6 (18)	3.6 (4)	.62
Stent Thrombosis (%)	0	0	–
TVR (non-TL) (%)	6.6 (21)	5.4 (6)	.82
TVF (%)	12.8 (41)	11.7 (13)	.87

*Non cardiac deaths (lung cancer and cerebral hemorrhage).

Kandzari et al. ACC, 2006.

ENDEAVOR III

Event Free Survival to 360 Days



	Endeavor	Cypher	*P* - value
TLR-free	93.4	96.5	.23
MACE-free	92.2	92.0	.93
TVF-free	87.2	88.5	.76

Kandzari et al. ACC, 2006.

ENDEAVOR II and III

Angiographic and Clinical Results

Angiographic Results (8 months)		E III n = 277	E II n = 264	*P*-value
Angiographic f/u %		85.8	88.6	.34
BAR (%)	In-Stent	9.7	9.5	1.00
	In-Segment	12.3	13.3	.80
Late Loss (mm)	In-Stent	0.62	0.62	.89
	In-Segment	0.36	0.36	.90
Clinical Results (9 months)		**E III n = 277**	**E II n = 264**	***P*-value**
TLR (%)		6.9	5.7	.60
MACE (%)		7.9	8.3	.88
TVF (%)		12.6	9.1	.22

ENDEAVOR IV

Randomized, Single-Blind, Multicenter Trial

Single *De Novo* Native
Coronary artery lesions Type: A-B
Lesion length ≤27 mm; RVD 2.5-3.5 mm
Pre-dilatation required

1:1 randomization
N = 1,548 patients
80 sites
US

Endeavor Stent
n = 774

Taxus Stent
n = 774

Clinical/MACE

30d | **6mo** | **8mo** | **9mo** | **12mo** | **2yr** | **3yr** | **4yr** | **5yr**

Angio/IVUS

QCA & IVUS Subset (328 total)

QCA/IVUS at 8 months for patients receiving >1 stent

Primary Endpoint: TVF at 9 mos
Secondary Endpoints: In-segment % DS at 8 mos; TSR and TVR at 9 mos; MACE 1, 6, 9, 12 mos
Antiplatelet therapy for ≥6 months. 10 μg Zotarolimus per mm stent length

ENDEAVOR Japan

Prospective, Multicenter, Single-Arm Study
Assessing Safety and Efficacy in a Japanese Population

Single *De Novo* Native
Coronary Artery Lesions (Type A-B2)
Stent Diameter: 2.25-3.5 mm
Stent Lengths: 18-30 mm (8/9 mm bailout)
Lesion Length: 14-27mm
Pre-dilatation required

N = 99 patients (includes 20 PK Sub-Study Patients)
11 sites in Japan



Angio N = 99 patients

Primary Endpoint: TVF (cardiac death, MI, TVR) at 9 months
Dual antiplatelet therapy for 3 months 10 μg Zotarolimus per mm stent length

Patient Flowchart

ENDEAVOR



Clinical Results at 30-Day

ENDEAVOR

	ENDEAVOR Japan N = 99	ENDEAVOR II N = 596	*P* Value
Composite MACE (%)	2.0	2.9	1.000
Death	0	0.2	1.000
Q-Wave MI	0	0.3	1.000
Non Q-Wave MI	2.0	2.3	1.000
Emergent CABG	0	0	—
TLR	0	0.8	1.000
TL-CABG	0	0	—
TL-PCI	0	0.8	1.000
TVR (%)	0	1.2	.601
Stent Thrombosis (%)	0	0.5	1.000
Acute ST	0	0.2	1.000
Sub-acute ST	0	0.3	1.000

ENDEAVOR

E-Five

Prospective, Multicenter Registry Assessing Safety in a Real World Patient Population

Single and Multiple Coronary Artery Lesions
Stent Diameters: 2.25-4.0 mm
Stent Length: 8/9-30 mm

N = 8,000 patients
200 sites
Europe, Asia Pacific, Israel, New Zealand, South America

Primary Endpoint: MACE at 12 months
Secondary Endpoints: MACE at 30 days and 6 mo, Stent thrombosis, procedure success rate; device success rate; lesion success rate
Antiplatelet therapy for ≥3 months **10 μg Zotarolimus per mm stent length**

*Limited number of centers and specific patient subset.

E-Five

Patient Demographics

	n = 2015
Male Gender (%)	76.6%
Age (years)	63.0±11.5
Prior MI (%)	37.4%
Non Q-wave MI	12.4%
Q wave MI	25.0%
Prior PCI (%)	24.0%
Prior CABG (%)	6.7%
Diabetes Mellitus (%)	35.2%
(Recent) MI (%)	21.8%
Unstable Angina (%)	31.5%

Lotan et al. TCT, 2006.

E-Five

Baseline Angiography (visual measurement)

	Endeavor n=2458*
LAD (%)	48.6
B2/C Lesions (%)	59.9
RVD (mm)	2.92
Lesion Length (mm)	18.28
Pre-procedure MLD (mm)	0.54
Pre-procedure DS (%)	81.53
Post-procedure DS (%)	2.13

*Number of lesions
Lotan et al. TCT, 2006.

E-Five

Procedure Characteristics

	n = 2458
Total Stent Length (mm)	23.4±12.0
Lesion Length (mm)	18.3±9.9
Stent:Lesion Length	1.4±0.5
Long lesions (>16 mm) (%)	45.2%
Smallest Endeavor Stent Diameter	
2.25 mm (%)	6.0%
2.5 mm (%)	21.4%
2.75 mm (%)	16.2%
3.0 mm (%)	34.9%
3.5 mm (%)	17.6%
4.0 mm (%)	3.8%

44%

The calculation includes all lesions with Endeavor stents implanted or attempted
Lotan et al. TCT, 2006.

E-Five

30-Day MACE

n =1982	Non Hierarchical
MACE	1.7% (34)
Death	0.9% (17)
MI (all)	0.9% (17)
Q-wave	0.3% (6)
Non Q-wave	0.6% (11)
Emergent CABG	0
TLR	0.4% (8)
TL-CABG	0
TL-PTCA	0.4% (8)

Lotan et al. TCT, 2006.

PROTECT Clinical Trial Design

ENDEAVOR

Proposed

Open Label
Dual APT >3 to ≤12 months

N = 8800
>200 International Sites
1:1 Randomization

Endeavor

Cypher

Clinical Follow-up

30d | 6mo | 9mo | 12mo | 18mo | 2yr | 3yr | 4yr | 5yr

Primary Endpoint: Definite or Probable Stent Thrombosis to 3 years
Secondary Endpoints: Death/NF MI, Cardiac death/NF MI, TVR, TLR
Co-PIs: W. Wijns (Belgium), P. Serruys (Netherlands), G. Steg (France), E. Camezind (Switzerland), B. O'Neill (USA)